Aristotle Capital Boston LLC Boosts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Aristotle Capital Boston LLC lifted its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 380,617 shares of the medical instruments supplier's stock after purchasing an additional 22,011 shares during the period. Aristotle Capital Boston LLC owned about 0.76% of Haemonetics worth $29,719,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Thrivent Financial for Lutherans increased its position in Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after acquiring an additional 164,111 shares during the period. Dimensional Fund Advisors LP increased its holdings in Haemonetics by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock valued at $77,470,000 after purchasing an additional 10,990 shares during the period. Boston Trust Walden Corp raised its position in Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Haemonetics by 0.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock worth $62,802,000 after buying an additional 5,668 shares during the period. Finally, Fisher Asset Management LLC grew its position in shares of Haemonetics by 3.2% in the 4th quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock valued at $55,575,000 after buying an additional 22,265 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Up 7.1 %

HAE traded up $4.56 during midday trading on Thursday, reaching $68.81. 598,349 shares of the company were exchanged, compared to its average volume of 692,811. The company has a market cap of $3.46 billion, a price-to-earnings ratio of 27.09, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a one year low of $55.30 and a one year high of $97.97. The company's fifty day moving average price is $62.64 and its 200 day moving average price is $71.49. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. During the same quarter in the prior year, the business earned $0.90 earnings per share. The firm's revenue for the quarter was down 3.5% on a year-over-year basis. As a group, analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on HAE shares. JMP Securities cut their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. StockNews.com upgraded Haemonetics from a "hold" rating to a "buy" rating in a report on Monday. Finally, Raymond James reissued a "strong-buy" rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Haemonetics presently has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.